sports writing journalism

sports writing journalism None

Y2K Digital Release Date Set for Rachel Zegler Disaster Comedy Movie

TCN boosts power supply in Lekki with new 75MVA transformer

Highway Safety's New Rule Faces Pushback from AutomakersInvesting in Eightfold Stock | How to Buy Pre-IPO Shares

CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.Gretchen McKay | (TNS) Pittsburgh Post-Gazette PITTSBURGH — Many Americans consider social media a scourge, but for a home cook, it can be a fun and informative place to get help deciding what to eat. Sure, some of the recipes would-be influencers recommend are in fact pretty abominable — check out @chefreactions on TikTok, Instagram or X for many, many examples — but I have stumbled across some pretty good recipes on many occasions, too. Related Articles Restaurants Food and Drink | ‘Tis the season for baking cookies Restaurants Food and Drink | Here are some last-minute holiday gift ideas Restaurants Food and Drink | Don’t shun pinot grigio! The good versions of wines you think are bad Restaurants Food and Drink | Quick Fix: Horseradish Crusted Snapper with Arugula Pasta Restaurants Food and Drink | Pizza to the rescue for a simple dinner One that’s been going viral for a while and but only recently caught my eye shines a spotlight on the creamy, tomatoey dish known as Marry Me chicken. There are probably as many recipes for Marry Me chicken on social media as there are cooks. (Delish claims to have created the video recipe for the original dish, also known as Tuscan chicken, in 2016.) But in my opinion, the best variations hang their chef’s hat on a sauce made with sun-dried tomatoes, garlic and cream. Yum! This rich and luxurious entree is a definite step above the “engagement” chicken that caused a similar stir when it made its debut in Glamour magazine in 2004. That proposal-worthy recipe — saved for posterity in the 2011 cookbook “100 Recipes Every Woman Should Know: Engagement Chicken and 99 Other Fabulous Dishes to Get You Everything You Want in Life” — featured a whole chicken roasted with lemon and herbs. Awesome for sure, but not nearly as swoon worthy. I’ve been married for a very long time, so I’m not looking for a dish that will get me engaged. But who wouldn’t want applause when they put dinner on the table? That’s how Delish’s original recipe made it into the latest installment of “Dinner for Four for $25.” Usually when I’m building these economical meals, I do all my shopping in one store. This time, I shopped over the course of a weekend at some of my favorite haunts to see if that made a difference. (And no, I didn’t factor in the cost of gas, but maybe should have!) First stop after downing my Saturday morning latte and Nutella mele at a street-side table at Colangelo’s in the Strip District: Wholey’s Market, where I found boneless chicken breast at the bargain price of $3.89 per pound. I then crossed the street and headed down the block to Pennsylvania Macaroni Co., where I found several varieties of sun-dried tomatoes to chose from. I went with a jar of Ponti sun-dried cherry tomatoes for $5.09 — a definite splurge when your budget is only $25, but an ingredient I knew would deliver plenty of flavor. At Aldi, I found a bag of five huge lemons for $3.89, or 78 cents apiece, and a nice package of fresh broccoli for $2.28. A bargain, considering I would only use about two-thirds of it. The German supermarket chain known for its low prices and no-frills shopping experience (you have to deposit a quarter to get a shopping cart) also had butter — a main ingredient in my sandwich cookie dessert — on sale for $3.99 a pound. A bag of powdered sugar was pretty cheap, too, at just $2.09 for a two-pound bag. “Shopping” my pantry for ingredients I always have on hand, including garlic, olive oil, spices, rice, molasses and vanilla, once again helped keep costs down. Total bill: $24.38, or 62 cents under budget. Not bad when you consider the homemade dessert recipe makes more oatmeal sandwich cookies than a family can/should eat at one sitting. Marry Me Chicken PG tested Sun-dried tomatoes could be considered a splurge item because even a tiny jar is expensive, but their concentrated, sweet and tangy tomato goodness add so much flavor to a dish! They are certainly the star of this chicken dish that has been making the rounds on social media platforms. Some say the entree is so good, you’ll get a marriage proposal out of it. At any rate, the Parmesan cream sauce that gets spooned on top of the chicken and rice will certainly make your diners swoon. This original recipe from Delish.com is a pretty easy dish to get on the table in quick fashion. Just remember to use a dry pot holder to take the pan out of the oven because it will be very hot; I very stupidly used a damp dish towel and now have another cooking scar. 4 (8-ounce) boneless, skinless chicken breasts Kosher salt Freshly ground black pepper 3 tablespoons extra virgin olive oil, divided 2 cloves garlic, finely chopped 1 tablespoons fresh thyme leaves 1 teaspoon crushed red pepper flakes 3/4 cup chicken broth 1/2 cup chopped sun-dried tomatoes packed in oil 1/2 cup heavy cream 1/4 cup finely grated Parmesan Fresh basil, torn, for serving, optional Cooked rice, for serving Preheat oven to 375 degrees. In a large ovenproof skillet over medium-high heat, heat 1 tablespoon oil. Generously season chicken with salt and black pepper and cook, turning halfway through, until golden brown, about 5 minutes per side. Transfer chicken to a plate. In same skillet over medium heat, heat remaining 2 tablespoons oil. Stir in garlic, thyme and red pepper flakes. Cook, stirring, until fragrant, about 1 minute. Stir in broth, tomatoes, cream, and Parmesan; season with salt. Bring to a simmer, then return chicken and any accumulated juices to skillet. Transfer skillet to oven. Bake chicken until cooked through and juices run clear when chicken is pierced with a knife, 10-12 minutes. Arrange chicken on a platter. Spoon sauce over. Top with basil, if using, and serve with cooked rice. Serves 4. — delish.com Broccoli with Lemon PG tested Broccoli is a reliable veggie when you need a little something extra to round out a meal and don’t want to spend a fortune. Here, it’s blanched until crisp-tender and then tossed with lemon juice and zest and a pinch of red pepper flakes. I used lemon olive oil (already on hand) for an extra burst of citrus flavor. 1 large bunch broccoli, separated into florets 2 tablespoons olive oil or butter 1 clove garlic, minced Juice and zest of 1/2 lemon 1 pinch (or two) red pepper flakes Flaky salt and freshly ground ground black pepper, to taste Place broccolini in a large skillet with about 2 inches of water; bring to a boil and cook until bright green, 1-2 minutes. Drain. Heat olive oil in the same skillet over medium heat. Stir in garlic and cook until golden and fragrant, 1-2 minutes. Add broccoli; cook and stir until heated through, 2-3 minutes. Squeeze lemon juice and zest over broccoli and season with red pepper flakes, salt, and pepper. Serves 4. — Gretchen McKay, Post-Gazette Oatmeal Cream Cookies PG tested Remember how if you were lucky when you were a kid you got an individually wrapped Little Debbie Oatmeal Creme Pie in your lunchbox? These soft and chewy oatmeal cookies sandwiched with vanilla buttercream taste exactly the same. Actually, they’re better because they’re not made with corn syrup and artificial flavorings, but rather real butter and brown sugar. It’s important to let the cookies cool on the baking sheet for a few minutes before transferring them to a rack. Otherwise they will fall apart. The icing is very sweet, so you might want to reduce the amount of powdered sugar. For cookies 1/2 cup unsalted butter, at room temperature 1 cup packed light brown sugar 1 tablespoon molasses 1 large egg, room temperature 1 teaspoon vanilla 1 1/4 cups all-purpose flour 1/2 cup old-fashioned oats 3/4 teaspoon baking soda 1/2 teaspoon salt For filling 1/2 cup unsalted butter, at room temperature 3 cups powdered sugar 2 tablespoons heavy cream 2 teaspoons vanilla Pinch of salt Preheat oven to 325 degrees and line two sheet pans with parchment paper. In stand mixer outfitted with whisk attachment add butter, brown sugar and molasses and beat on low speed until combined. Gradually increase speed to medium-high and beat until smooth, about 2 minutes. Scrape down sides and bottom of bowl with spatula, then add egg and vanilla extract. Beat on medium-high speed until combined. Add flour, oats, baking soda and salt and beat on low speed until just combined and no streaks of flour remain. Use a 1/2 -ounce cookie scoop tor tablespoon measure to portion out equal amounts of dough. Roll the dough in your hands to smooth the edges, then place 2 inches apart on prepared pans. Bake until cookies have puffed up and are set and firm around the edges but still somewhat soft in the middle, 9-11 minutes. Remove sheet pans from oven and allow cookies to rest on the pans for 5 minutes, then use a metal spatula to transfer cookies to a cooling rack to cool completely. Once cookies have cooled, make filling. In stand mixer fitted with the paddle attachment, combine butter, confectioners’ sugar, cream, vanilla and salt. Beat on low speed, gradually increasing the speed to high, until creamy and fully incorporated, about 45 seconds. If filling is dry, add a small splash or two of cream. Assemble cookies. Using a small offset spatula or butter knife to spread about 2 tablespoons of filling onto the bottom side of one cookie, then place second cookie on top to sandwich. Repeat with remaining cookies and serve. Makes 16 sandwich cookies. —”Sweet Tooth” by Sarah Fennel (Clarkson Potter, $35) ©2024 PG Publishing Co. Visit at post-gazette.com. Distributed by Tribune Content Agency, LLC.

By WILL WEISSERT, JUAN ZAMORANO and GARY FIELDS PANAMA CITY (AP) — Teddy Roosevelt once declared the Panama Canal “one of the feats to which the people of this republic will look back with the highest pride.” More than a century later, Donald Trump is threatening to take back the waterway for the same republic. Related Articles National Politics | President-elect Trump wants to again rename North America’s tallest peak National Politics | Inside the Gaetz ethics report, a trove of new details alleging payments for sex and drug use National Politics | An analyst looks ahead to how the US economy might fare under Trump National Politics | Trump again calls to buy Greenland after eyeing Canada and the Panama Canal National Politics | House Ethics Committee accuses Gaetz of ‘regularly’ paying for sex, including with 17-year-old girl The president-elect is decrying increased fees Panama has imposed to use the waterway linking the Atlantic and Pacific oceans. He says if things don’t change after he takes office next month, “We will demand that the Panama Canal be returned to the United States of America, in full, quickly and without question.” Trump has long threatened allies with punitive action in hopes of winning concessions. But experts in both countries are clear: Unless he goes to war with Panama, Trump can’t reassert control over a canal the U.S. agreed to cede in the 1970s. Here’s a look at how we got here: It is a man-made waterway that uses a series of locks and reservoirs over 51 miles (82 kilometers) to cut through the middle of Panama and connect the Atlantic and Pacific. It spares ships having to go an additional roughly 7,000 miles (more than 11,000 kilometers) to sail around Cape Horn at South America’s southern tip. The U.S. International Trade Administration says the canal saves American business interests “considerable time and fuel costs” and enables faster delivery of goods, which is “particularly significant for time sensitive cargoes, perishable goods, and industries with just-in-time supply chains.” An effort to establish a canal through Panama led by Ferdinand de Lesseps, who built Egypt’s Suez Canal, began in 1880 but progressed little over nine years before going bankrupt. Malaria, yellow fever and other tropical diseases devastated a workforce already struggling with especially dangerous terrain and harsh working conditions in the jungle, eventually costing more than 20,000 lives, by some estimates. Panama was then a province of Colombia, which refused to ratify a subsequent 1901 treaty licensing U.S. interests to build the canal. Roosevelt responded by dispatching U.S. warships to Panama’s Atlantic and Pacific coasts. The U.S. also prewrote a constitution that would be ready after Panamanian independence, giving American forces “the right to intervene in any part of Panama, to re-establish public peace and constitutional order.” In part because Colombian troops were unable to traverse harsh jungles, Panama declared an effectively bloodless independence within hours in November 1903. It soon signed a treaty allowing a U.S.-led team to begin construction . Some 5,600 workers died later during the U.S.-led construction project, according to one study. The waterway opened in 1914, but almost immediately some Panamanians began questioning the validity of U.S. control, leading to what became known in the country as the “generational struggle” to take it over. The U.S. abrogated its right to intervene in Panama in the 1930s. By the 1970s, with its administrative costs sharply increasing, Washington spent years negotiating with Panama to cede control of the waterway. The Carter administration worked with the government of Omar Torrijos. The two sides eventually decided that their best chance for ratification was to submit two treaties to the U.S. Senate, the “Permanent Neutrality Treaty” and the “Panama Canal Treaty.” The first, which continues in perpetuity, gives the U.S. the right to act to ensure the canal remains open and secure. The second stated that the U.S. would turn over the canal to Panama on Dec. 31, 1999, and was terminated then. Both were signed in 1977 and ratified the following year. The agreements held even after 1989, when President George H.W. Bush invaded Panama to remove Panamanian leader Manuel Noriega. In the late 1970s, as the handover treaties were being discussed and ratified, polls found that about half of Americans opposed the decision to cede canal control to Panama. However, by the time ownership actually changed in 1999, public opinion had shifted, with about half of Americans in favor. Administration of the canal has been more efficient under Panama than during the U.S. era, with traffic increasing 17% between fiscal years 1999 and 2004 . Panama’s voters approved a 2006 referendum authorizing a major expansion of the canal to accommodate larger modern cargo ships. The expansion took until 2016 and cost more than $5.2 billion. Panamanian President José Raúl Mulino said in a video Sunday that “every square meter of the canal belongs to Panama and will continue to.” He added that, while his country’s people are divided on some key issues, “when it comes to our canal, and our sovereignty, we will all unite under our Panamanian flag.” Shipping prices have increased because of droughts last year affecting the canal locks, forcing Panama to drastically cut shipping traffic through the canal and raise rates to use it. Though the rains have mostly returned, Panama says future fee increases might be necessary as it undertakes improvements to accommodate modern shipping needs. Mulino said fees to use the canal are “not set on a whim.” Jorge Luis Quijano, who served as the waterway’s administrator from 2014 to 2019, said all canal users are subject to the same fees, though they vary by ship size and other factors. “I can accept that the canal’s customers may complain about any price increase,” Quijano said. “But that does not give them reason to consider taking it back.” The president-elect says the U.S. is getting “ripped off” and “I’m not going to stand for it.” “It was given to Panama and to the people of Panama, but it has provisions — you’ve got to treat us fairly. And they haven’t treated us fairly,” Trump said of the 1977 treaty that he said “foolishly” gave the canal away. The neutrality treaty does give the U.S. the right to act if the canal’s operation is threatened due to military conflict — but not to reassert control. “There’s no clause of any kind in the neutrality agreement that allows for the taking back of the canal,” Quijano said. “Legally, there’s no way, under normal circumstances, to recover territory that was used previously.” Trump, meanwhile, hasn’t said how he might make good on his threat. “There’s very little wiggle room, absent a second U.S. invasion of Panama, to retake control of the Panama Canal in practical terms,” said Benjamin Gedan, director of the Latin America Program at the Woodrow Wilson International Center for Scholars in Washington. Gedan said Trump’s stance is especially baffling given that Mulino is a pro-business conservative who has “made lots of other overtures to show that he would prefer a special relationship with the United States.” He also noted that Panama in recent years has moved closer to China, meaning the U.S. has strategic reasons to keep its relationship with the Central American nation friendly. Panama is also a U.S. partner on stopping illegal immigration from South America — perhaps Trump’s biggest policy priority. “If you’re going to pick a fight with Panama on an issue,” Gedan said, “you could not find a worse one than the canal.” Weissert reported from West Palm Beach, Florida, and Fields from Washington. Amelia Thomson-Deveaux contributed to this report from Washington.

Luigi Mangione had the whole world at his fingertips. Until, authorities said, he pulled out a 3-D printed pistol Dec. 4 and shot Brian Thompson, the CEO of United Health, and fled to Altoona, Pennsylvania, where he was arrested at a McDonald’s restaurant. Now, Mangione is sitting in an isolation cell in SCI Huntingdon , a state prison located in the heart of the Appalachian region in Huntingdon County, Pennsylvania. On Thursday, the Pennsylvania Department of Corrections released an image of a cell “similar to” Mangione’s cell. Officials said the photo of an empty 15-by-6-foot prison cell shares a concrete wall with Mangione’s cell. It features a desk and stool; sink attached to a toilet; and an elevated concrete bed with a pad atop it. Suspect Luigi Mangione is taken into the Blair County Courthouse on Tuesday, Dec. 10, 2024, in Hollidaysburg, Pa. (Janet Klingbeil via AP) AP He’s being held on a firearms and forgery charges after police say he provided a false identity to Altoona officers. He has been denied bail as authorities work to get him back to New York to face murder charges in connection with Thompson’s death. He is fighting extradition, meaning he could be a guest of the Commonwealth for at least two more weeks. Mangione has been confined to his cell but will eventually get time outside his cell, according to Maria Bivens, department of corrections spokesperson. “That plan is being worked on right now. All state inmates are afforded time outside of their cells, even if they are [at] a higher custody level,” Bivens said. Mangione’s cell is situated in one of 14 housing units at the prison, according to the DOC. He is unable to see or interact with any other people incarcerated in his unit. Stories by Jonathan Bergmueller Dauphin County agency yanks contracts from political consultant after controversies Dauphin County polling place moved out of firehouse mired in theft, racial discrimination allegations What Luigi Mangione’s life looks like inside Pennsylvania prison( MENAFN - Newsfile Corp) Portland, Oregon--(Newsfile Corp. - December 23, 2024) - Renowned paranormal phenomena researcher and Hangar 1 Publishing author Thom Powell has issued a formal statement addressing recent speculation regarding the connection between mysterious drone sightings and the release of his latest book, "Planet Strange" (Hangar 1 Publishing, June 2024). Thom Powell's Planet Strange "While the timing has led to considerable speculation, I want to be absolutely clear that neither I nor anyone associated with my work has any involvement with the recent drone incidents," states Powell. "These sightings, though coincidentally aligned with themes explored in 'Planet Strange,' are entirely separate from my book's release and promotional activities." The statement comes in response to growing social media speculation linking the unexplained aerial phenomena to the book's publication. "Planet Strange," which examines various paranormal occurrences and their potential local origins, was released several months before the reported drone sightings began. Powell, whose research spans decades in the field of unexplained phenomena, emphasizes that such unfounded allegations detract from the serious nature of both the current sightings and the scholarly work presented in his book. "Hangar 1 Publishing stands firmly behind Thom Powell and his work," says Alex Hajicek, Publisher at Hangar 1 Publishing. "We believe in the integrity of our authors and the importance of addressing these phenomena with a scholarly approach." For more information about "Planet Strange" or to schedule an interview with Thom Powell, please contact the media representative at Hangar 1 Publishing. About Thom Powell Thom Powell is a respected author and researcher in the field of paranormal phenomena. His latest work, "Planet Strange," offers groundbreaking perspectives on unexplained aerial phenomena and their potential origins. The book is available through major retailers and Hangar 1 Publishing. About Hangar 1 Publishing Hangar 1 Publishing specializes in immersive, paranormal nonfiction-ranging from Bigfoot and cryptids to unexplained phenomena. With cutting-edge multimedia integration, our enhanced books deliver an unparalleled reading experience. For press inquiries, interviews, or review copies, please contact us directly. Press Inquiries MENAFN23122024004218003983ID1109025609 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

The TV program "Chinese Practice with Chinese Wisdom” Officially Airs: The Enduring Wisdom of Chinese Philosophy in Today's WorldKemi Badenoch eschewed customary slogans of a return to office when she embarked on her run for the Conservative leadership. Instead her lecterns and placards bore something rather more oblique: “Renewal 2030”. For Ms Badenoch, the distant choice of year reflects the seriousness of her mission: to retool the mainstream right for a new decade. Her restless detractors offer a less sympathetic interpretation. The new Tory leader, they complain, is proving so laggardly in setting out her stall that it will be five years before she deigns to explain what she stands for. Ms Badenoch was elected primarily for her strengths as a communicator. After their conclusive rejection by the electorate in July, and with Nigel Farage’s Reform UK monopolising momentum in British politics, her party needs those skills more than ever. Now the leadership is hers, however, Ms Badenoch’s natural supporters could be forgiven for detecting an uncharacteristic reticence. Unlike Robert Jenrick, the shadow justice secretary she defeated handsomely, she declined to offer substantive policy prescriptions during the leadership campaign and remains unrepentant.

Faizon Love argued that comedians shouldn't beef with one another while discussing Katt Williams' controversial comments about him from earlier this year. Williams labeled Love a "fat liar" while speaking with Shannon Sharpe for a now-infamous episode of Club Shay Shay back in January. He also joked about having a pot-bellied pig named after him at the GQ Men Of The Year event in November. Love responded to Williams during a recent interview on the We Playin' Spades podcast. "None of us should be beefing," Love said of comedians as a whole. "He loves me. He thinks about me all the time. These other comedians-- the white ones, they don't beef with each other." From there, he explained that he wasn't offended by Williams calling him "fat," but instead the accusation that he's a liar. Read More: How Hip-Hop Culture "Revived" Itself & Declared War On Its Leaders In 2024 BEVERLY HILLS, CA - FEBRUARY 21: Actors Faizon Love (L) and J.B. Smoove speak onstage during the 2016 ABFF Awards: A Celebration Of Hollywood at The Beverly Hilton Hotel on February 21, 2016 in Beverly Hills, California. (Photo by Alberto Rodriguez/BET/Getty Images for BET) While appearing on the Club Shay Shay podcast, Williams had ranted about several other comedians. In mentioning Love, he said: “I only put on comedians that are funnier than me. Anybody tell you different is a fat Faizon liar...Faizon said that getting a Netflix special is easy, I have 12 specials, guess how many Faizon got? Zero. Why is he allowed to have conversations about real stand-up people? We do not let people who are on the juice discuss real athletes, that’s all!” The We Playin' Spades podcast wasn't the first time Love addressed the rant. Taking to social media, earlier this year, he labeled the remarks: "lunacy, and hypocrisy, and downright ignorance." He also theorized that Williams was “ calling for help .” Check out Faizon Love's full comments on Katt Williams below. Read More: Ice Cube Opens Up About His New Album “Man Down,” Legacy, And The Future Of West Coast Hip-HopJets deliver payback to Leafs, claim NHL’s top spot before Christmas break

Wordle Hints, Clues And Answer Today #1280 December 20: Find the Word!

EAST RUTHERFORD, N.J. (AP) — If the Giants' franchise-record 10th straight loss proved anything, it's that New York could use a young franchise quarterback. Rookie Michael Penix Jr. showed what a young QB can do on Sunday against the Giants, who need to learn from it. The No. 8 overall pick in the draft, Penix played a nearly flawless game in his first career start to help the Falcons thrash the woeful Giants 34-7 in their best performance in weeks. The Giants gambled in 2019 that Daniel Jones would be their franchise QB and it really never panned out. The one exception was the 2022 season, when the No. 6 overall pick had a career year and led New York to a 9-7-1 record and a playoff berth in the first season after Joe Schoen was hired as general manager and Brian Daboll was named coach. The Giants even won a playoff game. With the release of Jones last month, the Giants (2-13) are now a team without a quarterback who can perform at the level required of an NFL starter. Tommy DeVito and Drew Lock have split the last four starts but neither has provided much of a spark for the league's worst offense. Lock handed the Falcons the game with two interceptions that were returned for touchdowns. To turn things around next season, the Giants must find a quarterback. “I’d say it’s very important,” Daboll said Monday. New York is going to have a high pick in the draft in Green Bay, Wisconsin, in late April. It could even be the No. 1 overall selection. Choosing the right quarterback is going to be hard. There isn't a can't-miss choice in 2025 draft and forcing one early would be a mistake. Unless the Giants are convinced that Cam Ward, Shedeur Sanders, Jalen Milroe or someone else is the next franchise player, they have have so many needs that it would be better to wheel and deal and fill as many holes as possible. Even if the Giants take a quarterback in the second round, there's bound to be someone available who has a chance to be better than what they have now. The calendar. The season ends in less than two weeks. The franchise is in disarray, and a shakeup appears likely. Daboll's future as the coach is not bright, considering the current skid and two straight losing seasons. Schoen has to share the blame and so do co-owners John Mara and Steve Tisch, who hired the GM and coach. LB Darius Muasau. The sixth-round draft pick out of UCLA has started the last three games since Bobby Okereke (back) was hurt and eventually put on injured reserve last week. Muasau had 11 tackles Sunday along with a quarterback hit and a tackle for a loss. He made the defensive calls after LB Micah McFadden left with a neck injury. Lock. In his starts, Lock has had three interceptions returned for touchdowns. He also lost a fumble on a strip-sack at Atlanta. Lock sustained a shoulder injury during the game and had an MRI on Monday. Besides Lock and McFadden, S Jason Pinnock (eye) also left the game. C John Michael Schmitz and RB Tyrone Tracy were evaluated for ankle injuries on Monday. 1 — Thanks to the Raiders' victory over the Jaguars, the Giants will have the No. 1 overall pick in the draft with two more losses. For the ninth and final time, the Giants will try to find a way to win at MetLife Stadium. New York is 0-8 heading into Sunday's game against the Indianapolis Colts. Its only other winless season at home was in 1974 when New York played at the Yale Bowl in New Haven, Connecticut, while Giants Stadium was being built. AP NFL: https://apnews.com/hub/nfl

Top Countries Making the Best Use of AI

A history of the Panama Canal — and why Trump can’t take it back on his own